Pharmacokinetics and Safety Study of Single and Multiple Oral Doses Prodarsan™ in Patients With Cockayne Syndrome

Study Description

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Brief Summary:

This study is to compare the exposure of orally administered Prodarsan to the intravenous dosed Osmitrol (10% solution) in Cockayne Syndrome (CS) patients. Also the pharmacokinetics of single and multiple orally dosed Prodarsan will be evaluated and compared to intravenous dose of Osmitrol in CS patients.

Condition or disease	Intervention/treatment	Phase
Cockayne Syndrome	Drug: Prodarsan	Phase 1; Phase 2

Study Design

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Study Type :	Interventional (Clinical Trial)
Actual Enrollment :	5 participants
Allocation:	Non-Randomized
Intervention Model:	Single Group Assignment
Masking:	None (Open Label)
Official Title:	A Phase I/II Crossover Study To Evaluate and Compare the Pharmacokinetics of a Single IV Dose of D-Mannitol (Osmitrol®10%) to Single and Multiple, Escalating Doses of Liquid, Oral Prodarsan™ in Patients With Cockayne Syndrome
Study Start Date :	June 2010
Actual Primary Completion Date :	September 2010
Actual Study Completion Date :	February 2011

Arms and Interventions

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm	Intervention/treatment
Experimental: oral, liquid solution	Drug: Prodarsan; Prodarsan TID, oral solution, 6-8 days

Outcome Measures

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :

1. Evaluate and compare the pharmacokinetics of D-mannitol following a single IV dose of Osmitrol to single and multiple oral doses of Prodarsan in pediatric patients with Cockayne Syndrome [ Time Frame: 6 months ]

Secondary Outcome Measures :

1. Evaluate the safety and tolerability of administering oral Prodarsan in CS patients over a six (6) to eight (8) day period, including dose escalation to reach a Target Dose [ Time Frame: 6 months ]

Eligibility Criteria

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Ages Eligible for Study:	2 Years to 10 Years (Child)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

• Parents or legal guardian(s) of the pediatric patient with CS must be willing and able to give written Informed Consent. Informed Assent will be offered to children who can understand and participate in the Informed Assent process.

• Diagnosis of CS confirmed by one of the following laboratory diagnostic test results:

  • Demonstration by molecular diagnostic analyses of two mutations in either the ERCC6 gene or the ERCC8 gene, wherein both mutations are either known to be pathogenic or are obviously detrimental (including nonsense or frameshift mutations, mutations of "invariant" splice site consensus signals, or large deletions/rearrangements); OR
  • A pattern of DNA repair responses in patient's cultured skin fibroblast cells indicative of a specific deficiency of transcription-coupled DNA nucleotide excision repair after irradiation with ultraviolet light, namely a significant deficiency of cellular survival (and/or "recovery of ribonucleic acid [RNA] synthesis," if that has been specifically measured) coupled with a normal test for "unscheduled DNA synthesis" OR
  • Decreased cell survival and/or "recovery of RNA synthesis" in UV-irradiated patient's skin fibroblast cultures and rescue of these parameters by fusion to reference cell lines with known NER defects (functional complementation analysis) OR
  • Quantitative RT-PCR to quantify mRNA levels of CS-A and CS-B transcripts.
• Weight inclusive of 10 kg to 25 kg.
• Male or female, inclusive of two (2) to ten (10) years of age.
• Clinically acceptable hematocrit as judged by the Principal Investigator (PI).
• The investigator has the opinion that the patient and caregiver are willing and able to comply with protocol requirements.

Exclusion Criteria:

• Any concurrent illness (other than related to CS), disability or clinically significant abnormality, including laboratory tests, that may affect the interpretation of the PK or safety data or prevent the patient from safely completing the assessments required by the protocol as judged by the investigator. Such conditions include, but are not limited to:

  • Ascites or generalized edema.
  • Nephrotic syndrome or history of abnormal kidney function.
  • Clinically significant thyrotoxicosis.
  • Known history of hyperprolinemia.
  • Clinically significant dehydration as judged by the investigator
• Severely compromised venous access.
• Presence of an external ventricular, abdominal, or chest drain.
• Subjects due to receive radioiodine therapy, two (2) weeks before or two (2) weeks following the study period.
• Participation in another PK or treatment clinical study within thirty (30) days prior to signing and dating of Informed Consent/Assent Form for this study.

• As judged by the investigator, clinical features present at the time of initial screening, that are associated with the terminal phases of the natural progression of CS, indicating that safe travel and completion of the study and its assessments are unlikely, including any of the following:

  • Continuous or intermittent dependence on supplemental oxygen at home during the six (6) months prior to enrollment in this study; OR
  • Two or more hospitalizations due to pneumonia, during the twelve (12) months prior to enrollment in this study; OR
  • A documented, net weight loss of at least 10%, which has not been recovered, and which includes a significant net weight loss (beyond the estimated error of the measurement) over the most recent 6 months despite intensive nutritional support including the use of gastrostomy tube feedings.
• Known hypersensitivity to any of the components found in Prodarsan, D-mannitol, iohexol or iodine compounds.
• History of clinically significant drug sensitivity or allergic reaction such as anaphylaxis.

Contacts and Locations

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Locations

United States, Massachusetts
Children's Hospital Boston
Boston, Massachusetts, United States, 02115

Sponsors and Collaborators

DNage B.V.

Investigators

Principal Investigator:	Edward Neilan, MD	Boston Children’s Hospital

More Information

Go to 

Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Responsible Party:	Lia Dam/Director Clinical Operations, DNage
ClinicalTrials.gov Identifier:	NCT01142154 History of Changes
Other Study ID Numbers:	MP1104-02
First Posted:	June 11, 2010
Last Update Posted:	June 23, 2011
Last Verified:	June 2011

Keywords provided by DNage B.V.:

Cockayne Syndrome; Ageing; pediatrics; Pharmacokinetics; Prodarsan	Dwarfism; Genetic disease, inborn; DNA Repair-Deficiency Disorders; Tolerability; Safety

Additional relevant MeSH terms:

Syndrome; Cockayne Syndrome; Disease; Pathologic Processes; Dwarfism; Bone Diseases, Developmental; Bone Diseases; Musculoskeletal Diseases	Heredodegenerative Disorders, Nervous System; Neurodegenerative Diseases; Nervous System Diseases; Abnormalities, Multiple; Congenital Abnormalities; Genetic Diseases, Inborn; DNA Repair-Deficiency Disorders; Metabolic Diseases